2μg (R: reducing condition).
Product Details
Product Details
Product Specification
Species | Human |
Synonyms | CD126,gp80,IL-6R-1,IL-6RA,IL6Q,IL6RA,IL6RQ |
Amino Acid Sequence | Leu20-Pro365 with His &Avi Tag at the C-terminus |
Expression System | HEK293 |
Molecular Weight | 55-72 kDa(Reducing) |
Purity | >95% by SDS-PAGE |
Endotoxin | <0.1EU/μg |
Conjugation | Biotin |
Tag | Avi Tag, His Tag |
Physical Appearance | Lyophilized powder |
Storage Buffer | PBS PH7.4 5% trehalose |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
Reference | Barill S, et al. (2000) The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw. 11(4): 546-51. |
Background
Interleukin-6 receptor (IL-6R, CD126) is the ligand-binding subunit of a heterodimeric type-I cytokine receptor that partners with the common signal-transducer gp130. Both membrane-bound and soluble forms (sIL-6R) generated by proteolytic shedding can trigger IL-6 signaling. While the membrane receptor mediates “classic” signaling, the IL-6/sIL-6R complex engages gp130 on cells lacking endogenous IL-6R, enabling “trans-signaling” that markedly amplifies IL-6’s pleiotropic effects on growth, differentiation, and immune responses. Dysregulation of IL-6 and IL-6R is implicated in chronic inflammation, autoimmunity (e.g., rheumatoid arthritis), osteoporosis, and malignancies such as multiple myeloma, making these molecules validated therapeutic targets, exemplified by humanized anti-IL-6R monoclonal antibodies.
Picture
Picture
SDS-PAGE
ELISA
Immobilized Human IL-6 (Cat. No. UA040052) at 5.0μg/mL (100μL/well) can bind Biotinylated IL-6R alpha/CD126 Avi&His Tag Protein, Human (Cat. No. UA011248) with EC50 of 78.37-140.2ng/mL.
